Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...
The evolution of clinical trials is being driven by an increased focus on patient perspectives and innovative statistical methodologies. Regulatory agencies are pushing for trials that better ...
We ran a Q&A with John Clarke, associate director in patient recruitment at Innovaderm on the changing landscape of patient centricity in terms of clinical trials and how the industry can navigate the ...
Australian contract development and manufacturing organizations (CDMOs), BioCina and NovaCina, have merged in a move to pool their biologic and small molecule production expertise and infrastructure.
We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...